Evidence map›Paper›PMID 37831752›Full record

ArticleNeurogastroenterology and motility2023

Protective actions of a luminally acting 5-HT

Molly Hurd, Melody M Haag, Matthew J Kwasnik, Jill Wykosky, Brigitte Lavoie, Gary M Mawe

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurogastroenterology and motility, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Molly HurdDepartment of Neurological Sciences, The University of Vermont, Burlington, Vermont, USA.
Melody M HaagDepartment of Neurological Sciences, The University of Vermont, Burlington, Vermont, USA.
Matthew J KwasnikDepartment of Neurological Sciences, The University of Vermont, Burlington, Vermont, USA.
Jill WykoskyTakeda Pharmaceuticals Company Limited, Cambridge, Massachusetts, USA.
Brigitte LavoieDepartment of Neurological Sciences, The University of Vermont, Burlington, Vermont, USA.
Gary M MaweDepartment of Neurological Sciences, The University of Vermont, Burlington, Vermont, USA.ORCID 0000-0001-8876-8468
University of Vermont · USTakeda (United States) · US

Funding

Mechanisms of gallbladder smooth muscle dysfunctionR01DK131044 · NIDDK · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI LAVOIE, BRIGITTE · 2022 to 2025
$2.2M
Use of tryptophan-synthesizing bacteria to enhance intestinal motilityR21AT011203 · NCCIH · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI LAVOIE, BRIGITTE · 2021 to 2022
$421k
NCCIH NIH HHS R21 AT011203NIDDK NIH HHS R01 DK131044
6 · The paper itself

Abstract

background5-hydroxytryptamine 4 receptors (5-HT

methodsThe dextran sodium sulfate (DSS), trinitrobenzene sulfonic acid (TNBS), and interleukin 10 knockout (IL-10KO) models of colitis were used to test the protective effects of the luminally acting 5-HT KEY

resultsDaily enema of 5HT4-LA1 attenuated the development of, and accelerated recovery from, active colitis. Enema administration of 5HT4-LA1 did not attenuate the development of colitis in 5-HT CONCLUSIONS AND INFERENCES: Luminally restricted 5-HT

Indexed as

ColitisSerotoninAnimalsCaco-2 CellsHumansMiceMice, KnockoutWaterSerotoninWater5-HT4 receptorcolitismucosal serotonin signaling

Identifiers

PMID37831752
PMCPMC10840927
OpenAlexW4387611483

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.